- Home
- YSWY vs SLBT Comparison
YSWY vs SLBT Comparison
Compare YSWY & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$24.91
Company Overview
Basic Information| Metric | YSWY | SLBT |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Food Chains | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | YSWY | SLBT |
|---|---|---|
| Price | $24.91 | $2.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 354.2K | 56.1K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.92 | $2.54 |
| 52 Week High | $26.34 | $6.25 |
Technical Indicators
Market Signals| Indicator | YSWY | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 67.06 | 43.53 |
| Support Level | $19.41 | $2.54 |
| Resistance Level | $26.34 | $2.89 |
| Average True Range (ATR) | 1.29 | 0.14 |
| MACD | 0.27 | 0.06 |
| Stochastic Oscillator | 88.79 | 54.84 |
Price Performance
Historical Comparison YSWY
SLBT
About SLBT SL Science Holding Limited Ordinary Shares
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.